BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 26405697)

  • 1. Infliximab Therapy for Corticosteroid-Resistant Ipilimumab-Induced Colitis.
    Beniwal-Patel P; Matkowskyj K; Caldera F
    J Gastrointestin Liver Dis; 2015 Sep; 24(3):274. PubMed ID: 26405697
    [No Abstract]   [Full Text] [Related]  

  • 2. Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis.
    Jain A; Lipson EJ; Sharfman WH; Brant SR; Lazarev MG
    World J Gastroenterol; 2017 Mar; 23(11):2023-2028. PubMed ID: 28373768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ipilimumab-induced colitis in patients with metastatic melanoma.
    De Felice KM; Gupta A; Rakshit S; Khanna S; Kottschade LA; Finnes HD; Papadakis KA; Loftus EV; Raffals LE; Markovic SN
    Melanoma Res; 2015 Aug; 25(4):321-7. PubMed ID: 25933207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ipilimumab associated colitis: an IpiColitis case series at MedStar Georgetown University Hospital.
    Rastogi P; Sultan M; Charabaty AJ; Atkins MB; Mattar MC
    World J Gastroenterol; 2015 Apr; 21(14):4373-8. PubMed ID: 25892889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab for severe colitis associated with nivolumab followed by ipilimumab.
    Fukumoto T; Fujiwara S; Tajima S; Tamesada Y; Sakaguchi M; Oka M; Nishigori C
    J Dermatol; 2018 Jan; 45(1):e1-e2. PubMed ID: 28891241
    [No Abstract]   [Full Text] [Related]  

  • 6. Ipilimumab-induced acute severe colitis treated by infliximab.
    Pagès C; Gornet JM; Monsel G; Allez M; Bertheau P; Bagot M; Lebbé C; Viguier M
    Melanoma Res; 2013 Jun; 23(3):227-30. PubMed ID: 23458760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of toxicities of immune checkpoint inhibitors.
    Spain L; Diem S; Larkin J
    Cancer Treat Rev; 2016 Mar; 44():51-60. PubMed ID: 26874776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab for IPILIMUMAB-Related Colitis-Letter.
    Arriola E; Wheater M; Karydis I; Thomas G; Ottensmeier C
    Clin Cancer Res; 2015 Dec; 21(24):5642-3. PubMed ID: 26672088
    [No Abstract]   [Full Text] [Related]  

  • 9. Systematic review: colitis associated with anti-CTLA-4 therapy.
    Gupta A; De Felice KM; Loftus EV; Khanna S
    Aliment Pharmacol Ther; 2015 Aug; 42(4):406-17. PubMed ID: 26079306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vedolizumab: a novel treatment for ipilimumab-induced colitis.
    Hsieh AH; Ferman M; Brown MP; Andrews JM
    BMJ Case Rep; 2016 Aug; 2016():. PubMed ID: 27539137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ipilimumab-induced colitis: a rare but serious side effect.
    Hinds AM; Ahmad DS; Muenster JE; Berg ZM; Lopez KT; Holly JS; Matteson-Kome ML; Bechtold ML
    Endoscopy; 2014; 46 Suppl 1 UCTN():E308-9. PubMed ID: 25058826
    [No Abstract]   [Full Text] [Related]  

  • 12. PD-1 Antibody-induced Guillain-Barré Syndrome in a Patient with Metastatic Melanoma.
    Schneiderbauer R; Schneiderbauer M; Wick W; Enk AH; Haenssle HA; Hassel JC
    Acta Derm Venereol; 2017 Mar; 97(3):395-396. PubMed ID: 27868138
    [No Abstract]   [Full Text] [Related]  

  • 13. Colitis associated with biological agents.
    Khirfan K; Kistin M
    Dig Dis Sci; 2014 Jun; 59(6):1112-4. PubMed ID: 24756315
    [No Abstract]   [Full Text] [Related]  

  • 14. Balancing the Checkpoint: Managing Colitis Associated with Dual Checkpoint Inhibitors and High-Dose Aspirin.
    Hammami MB; Gill R; Thiruvengadam N; Oh DY; Beck K; Mahadevan U; Kattah MG
    Dig Dis Sci; 2019 Mar; 64(3):685-688. PubMed ID: 30778872
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunological Characteristics of Colitis Associated with Anti-CTLA-4 Antibody Therapy.
    Bamias G; Delladetsima I; Perdiki M; Siakavellas SI; Goukos D; Papatheodoridis GV; Daikos GL; Gogas H
    Cancer Invest; 2017 Aug; 35(7):443-455. PubMed ID: 28548891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment possibilities of ipilimumab-induced thrombocytopenia--case study and literature review.
    Kopecký J; Trojanová P; Kubeček O; Kopecký O
    Jpn J Clin Oncol; 2015 Apr; 45(4):381-4. PubMed ID: 25583422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus.
    Yamamoto S; Nakase H; Matsuura M; Honzawa Y; Masuda S; Inui K; Chiba T
    J Gastroenterol Hepatol; 2010 May; 25(5):886-91. PubMed ID: 20546441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycophenolate mofetil alongside high-dose corticosteroids: optimizing the management of combination immune checkpoint inhibitor-induced colitis.
    Mir R; Shaw HM; Nathan PD
    Melanoma Res; 2019 Feb; 29(1):102-106. PubMed ID: 30395075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab.
    Johnston RL; Lutzky J; Chodhry A; Barkin JS
    Dig Dis Sci; 2009 Nov; 54(11):2538-40. PubMed ID: 19104936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ipilimumab in a patient with known Crohn's disease: to give or not to give?
    Gielisse EA; de Boer NK
    J Crohns Colitis; 2014 Dec; 8(12):1742. PubMed ID: 25154682
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.